Diabetes and the Heart
Diabetes and Glycemic Control -
Endocrine
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: November 4, 2009
Renewal Date: November 14, 2011
Expiration Date: November 14, 2012
Estimated Time of Completion: 1 hour, 30 minutes
Description
The Diabetes and the Heart webcast series is composed of selected presentations from Diabetes and the Heart: A Clinical Summit on Critically Challenging Patients, a live symposium held August 6-7, 2009. The Summit was the inaugural educational activity of the Joslin Diabetes Center and Cleveland Clinic partnership.
With the increase in prevalence of the cardiometabolic syndrome and its comorbidities, the need to optimize preventive and therapeutic interventions is a major focus of most clinicians in primary care. Certainly, clinicians must recognize the signs and symptoms of the cardiometabolic syndrome and initiate early and effective preventive interventions. However, timely diagnosis and appropriate treatment are equally as important to reduce eventual morbidity and mortality.
Learning Objectives
- Identify the role of visceral fat in comparison with subcutaneous fat in the pathogenesis of insulin resistance and coronary artery disease in patients with diabetes.
- Identify the clinical interventions that may reduce visceral fat.
- Describe the pathophysiology of diabetes and obesity.
- Discuss the mechanism of action of various bariatric procedures on diabetes improvement.
- Recognize the relative risks and benefits of bariatric surgery specific to diabetes and cardiac disease management.
- Describe the indications and contraindications of bariatric surgery.
Target Audience
Primary care physicians, endocrinologists, cardiologists, nurse practitioners, physician assistants, nurses and other allied healthcare professionals will find this webcast valuable in their daily practice.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the
Accreditation Council for Continuing Medical Education to provide continuing medical
education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Directors| Richard S. Beaser, MD Medical Executive Director of Professional Education Joslin Diabetes Center Boston, MA |
James B. Young, MD Institute Chairman Endocrinology and Metabolism Institute Cleveland Clinic Cleveland, OH |
Robert S. Zimmerman, MD Director, Fellowship Program Endocrinology and Metabolism Institute Cleveland Clinic Cleveland, OH |
Faculty
| Osama Hamdy, MD, PhD, FACE Medical Director Obesity Clinical Program Joslin Diabetes Center Harvard Medical School Boston, MA |
Sangeeta Kashyap, MD Endocrinology and Metabolism Institute Cleveland Clinic Cleveland, OH |
Philip Schauer, MD Bariatric and Metabolic Institute Cleveland Clinic Cleveland, OH |
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation
Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation
Center for Continuing Education requires resolution of all faculty conflicts of interest to
ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:
| Osama Hamdy, MD, PhD, FACE | |||
| Amylin Pharmaceuticals; Merck & Company; Novo Nordisk; Sanofi Aventis; Takeda Pharmaceuticals |
Teaching and Speaking | ||
| Philip Schauer, MD | MISS Surgery Symposium; Partner; Remedy MD | Board of Directors | |
| Bard-Davol; Baxter; Ethicon Endosurgery; Gore; Physician Reviews of Surgery |
Consulting | ||
| Dowden-Contemporary Surgery Journal; Surgery for Obesity & Related Diseases |
Editor | ||
| Stryker Endoscopy | Other Advisory Board | ||
| Remedy MD | Partner | ||
| Invacare | Research | ||
| Bard-Davol; Barosense; Ethicon Endosurgery; Stryker Endoscopy | Scientific Advisory Board | ||
| James B. Young, MD | |||
| AstraZeneca; Gilead Sciences, Inc.; GlaxoSmithKline | Consulting | ||
| AstraZeneca | Independent Contractor | ||
| AstraZeneca; Gilead Sciences, Inc.; GlaxoSmithKline | Review Panels | ||
| Robert S. Zimmerman, MD | |||
| GlaxoSmithKline; Novo Nordisk | Teaching and Speaking | ||
The following faculty have indicated that they have no relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:
Richard S. Beaser, MD
Sangeeta Kashyap, MD
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:
Amylin Pharmaceuticals, Inc. and Lilly USA, LLC
Athena Diagnostics, Inc.
Daiichi Sankyo, Inc.
Merck & Co., Inc.
St. Jude Medical
This CME activity was produced by
the Cleveland Clinic Endocrinology and Metabolism Institute,
the Center for Continuing Education, and the Joslin Diabetes Center.
